title: Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial.
abstract: OBJECTIVE
  To determine the incremental cost-effectiveness ratios (ICERs) of two therapeutic regimens of infliximab for ankylosing spondylitis (AS).
  
  
  METHODS
  230 patients with active AS who were participating in a randomised controlled trial comparing two infliximab infusion modalities-every 6 weeks (Q6) and on demand (DEM)-were included in an economic evaluation within the trial. Data were collected by phone every 3 months for 1 year. Direct and indirect costs were calculated from a payer perspective. Health-related quality of life was assessed with a general health rating scale. ICERs were calculated for one 20% improvement (ASAS20), for one partial remission and for one quality-adjusted life year (QALY) gained.
  
  
  RESULTS
  The Q6 regimen was significantly more efficacious than the DEM regimen but also more costly (euro22 388 vs euro17 596; p<0.001), because it required significantly more infliximab infusions per patient (8.4 vs 6.2). The ICERs of the Q6 to DEM regimen were euro15 841 for one ASAS20 response, euro23 296 for one partial remission and euro50 760 for one QALY gained.
  
  
  CONCLUSIONS
  The administration of infliximab every 6 weeks is cost effective as compared with a DEM regimen; however, the ICER is close to the acceptability threshold of euro50 000 for one QALY gained.
  
  
  BACKGROUND
  NCT 00439283.
authors.affiliation: APHP, Groupe hospitalier Pitié-Salpêtrière, Service of Rhumatologie, Paris, France. bruno.fautrel@psl.aphp.fr
authors.forename: B
authors.initials: B
authors.lastname: Fautrel
authors.forename: M
authors.initials: M
authors.lastname: Benhamou
authors.forename: M
authors.initials: M
authors.lastname: Breban
authors.forename: C
authors.initials: C
authors.lastname: Roy
authors.forename: C
authors.initials: C
authors.lastname: Lenoir
authors.forename: G
authors.initials: G
authors.lastname: Trape
authors.forename: A
authors.initials: A
authors.lastname: Baleydier
authors.forename: P
authors.initials: P
authors.lastname: Ravaud
authors.forename: M
authors.initials: M
authors.lastname: Dougados
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D016527:Drug Costs / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000191:economics; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab